Overview

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

In this study positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer [18F]fluorothymidine (FLT).

Phase:

Phase 1

Details

Lead Sponsor:

Abramson Cancer Center of the University of Pennsylvania
University of Pennsylvania

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel